Filing Flows › Comparisons › BIOE vs IRD
Bio Essence vs Opus Genetics: BIOE and IRD compared
Bio Essence is the larger company: $795K of revenue in its latest quarter (Q2 2026) against $755K for Opus Genetics (Q2 2026). Bio Essence is growing faster (+207% against -74% a year earlier).
Where the money goes: BIOE and IRD
Bio Essence (BIOE) · Q2 2026
Bio Essence, Q2 2026: revenue $795K (+207% year over year), operating margin 35.1%, net earnings $270K, operating cash flow $60K. The chart follows the revenue to costs, profit and cash.
Opus Genetics (IRD) · Q2 2026
Opus Genetics, Q2 2026: revenue $755K (-74% year over year), net loss $8.1M, operating cash flow −$11.9M. The chart follows the revenue to costs, profit and cash.
| Bio Essence (BIOE) | Opus Genetics (IRD) | |
|---|---|---|
| Latest quarter | Q2 2026 | Q2 2026 |
| Revenue | $795K | $755K |
| Revenue growth, Y/Y | +207% | -74% |
| Gross margin | 59.2% | — |
| Operating margin | 35.1% | n/m |
| Net earnings | $270K | −$8.1M |
| Net margin | 34.0% | — |
| Operating cash flow | $60K | −$11.9M |
Questions
Which is bigger, Bio Essence or Opus Genetics?
Bio Essence is the larger company: $795K of revenue in its latest quarter (Q2 2026) against $755K for Opus Genetics (Q2 2026).
Is Bio Essence or Opus Genetics growing faster?
Bio Essence is growing faster (+207% against -74% a year earlier).
More: Bio Essence earnings · how Bio Essence makes money · Opus Genetics earnings · how Opus Genetics makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Aug 14, 2026; 10-Q filed Aug 6, 2026). Fiscal quarters can end on different dates. Not investment advice.